The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Selection of Mutations in the Hepatitis B Virus Polymerase During Therapy of Transplant Recipients With Lamivudine
Open accessAbstract
We describe mutations in the hepatitis B virus (HBV) polymerase gene in viruses which reactivated in two patients during therapy with –2′–deoxy– 3′–thiacytidine, or lamivudine (3TC), and following orthotopic liver transplantation for chronic hepatitis B. Virus resistance to 3TC is associated with mutations which lead to amino acid substitutions in the highly conserved tyr–met–asp–asp (YMDD) motif, part of the active site of the polymerase, and which parallel those seen in resistant human immunodeficiency virus (HIV). Substitutions of valine and isoleucine for methionine were found in the two cases. The significance of single secondary mutations, which differ between viruses from the two patients, remains to be determined. Thus, viral resistance to lamivudine of hepatitis B virus mimics that of HIV and can occur in the setting of immunosuppression after liver transplantations.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A comprehensive set of sequence analysis programs for the VAX
Devereux, J., Haeberli, P., & Smithies, O. (1984) · Nucleic Acids Research · doi:10.1093/nar/12.1part1.387 · Cited by 14,222
Crystal structure at 3.5 A resolution of HIV-1 reverse transcriptase complexed with an inhibitor
Kohlstaedt, L. A., Wang, J., Friedman, J. M., Rice, P. A., & Steitz, T. A. (1992) · Science · doi:10.1126/science.1377403 · Cited by 1,914
A Preliminary Trial of Lamivudine for Chronic Hepatitis B Infection
Dienstag, J. L., Perrillo, R. P., Schiff, E. R., Bartholomew, M., Vicary, C., & Rubin, M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199512213332501 · Cited by 800
Tisdale, M., Kemp, S. D., Parry, N. R., & Larder, B. A. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.12.5653 · Cited by 603
Toh, H., Hayashida, H., & Miyata, T. (1983) · Nature · doi:10.1038/305827a0 · Cited by 458
Tbe complete nudeotide sequences of the cloned hepatitis B vims DNA; subtype adr and adw
Ono, Y., Onda, H., Sasada, R., Igarashi, K., Sugino, Y., & Nishioka, K. (1983) · Nucleic Acids Research · doi:10.1093/nar/11.6.1747 · Cited by 427
Norder, H., Hammas, B., Lee, S.-D., Bile, K., Courouce, A.-M., Mushahwar, I. K., & Magnius, L. O. (1993) · Journal of General Virology · doi:10.1099/0022-1317-74-7-1341 · Cited by 338
Larder, B. A., Kemp, S. D., & Purifoy, D. J. M. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.13.4803 · Cited by 179
New nucleoside analogues for chronic hepatitis B.
Schalm, S. W., de Man, R. A., Heijtink, R. A., & Niesters, H. G. M. (1995) · PubMed · Cited by 56
Cited by
Lee, W. M. (1997) · New England Journal of Medicine · doi:10.1056/nejm199712113372406 · Cited by 2,569
A One-Year Trial of Lamivudine for Chronic Hepatitis B
Lai, C.-L., Chien, R.-N., Leung, N. W. Y., Chang, T.-T., Guan, R., Tai, D.-I., Ng, K.-Y., Wu, P.-C., Dent, J. C., Barber, J., et al. (1998) · New England Journal of Medicine · doi:10.1056/nejm199807093390201 · Cited by 1,754
Sarin, S. K., Kedarisetty, C. K., Abbas, Z., Amarapurkar, D., Bihari, C., Chan, A. C. Y., Chawla, Y. K., Dokmeci, A. K., Garg, H., Ghazinyan, H., et al. (2014) · Hepatology International · doi:10.1007/s12072-014-9580-2 · Cited by 1,481
“In patients with chronic HBV infection, prolonged lamivudine therapy that exceeds 6 months is reportedly associated with an increased risk of treatment-induced HBV variants with YMDD mutations [73]; so alternative treatments with adefovir, tenofovir, or entecavir should be tested [74].”
Seeger, C., & Mason, W. S. (2000) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.64.1.51-68.2000 · Cited by 1,451
Lamivudine as Initial Treatment for Chronic Hepatitis B in the United States
Dienstag, J. L., Schiff, E. R., Wright, T. L., Perrillo, R. P., Hann, H.-W. L., Goodman, Z., Crowther, L., Condreay, L. D., Woessner, M., Rubin, M., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199910213411702 · Cited by 1,226
The Treatment of Chronic Viral Hepatitis
Hoofnagle, J. H., & Di Bisceglie, A. M. (1997) · New England Journal of Medicine · doi:10.1056/nejm199701303360507 · Cited by 946
Identification and characterization of mutations in hepatitis B virus resistant to lamivudine
Allen, M. I., Deslauriers, M., Andrews, W. C., Tipples, G. A., Walters, K.-A., Tyrrell, D. L., Brown, N., & Condreay, L. D. (1998) · Hepatology · doi:10.1002/hep.510270628 · Cited by 793
Management of hepatitis B: 2000—Summary of a workshop
Lok, A. S., Heathcote, E. J., & Hoofnagle, J. H. (2001) · Gastroenterology · doi:10.1053/gast.2001.24839 · Cited by 776
Sarin, S. K., Kumar, A., Almeida, J. A., Chawla, Y. K., Fan, S. T., Garg, H., de Silva, H. J., Hamid, S. S., Jalan, R., Komolmit, P., et al. (2009) · Hepatology International · doi:10.1007/s12072-008-9106-x · Cited by 763
Virus dynamics and drug therapy
Bonhoeffer, S., May, R. M., Shaw, G. M., & Nowak, M. A. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.13.6971 · Cited by 632
Management of hepatitis B: Summary of a clinical research workshop†
Hoofnagle, J. H., Doo, E., Liang, T. J., Fleischer, R., & Lok, A. S. F. (2007) · Hepatology · doi:10.1002/hep.21627 · Cited by 628
Markowitz, J. S., Martin, P., Conrad, A. J., Markmann, J. F., Seu, P., Yersiz, H., Goss, J. A., Schmidt, P., Pakrasi, A., Artinian, L., et al. (1998) · Hepatology · doi:10.1002/hep.510280241 · Cited by 485
Shouval, D. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(03)00152-1 · Cited by 470
Lok, A. S., Zoulim, F., Locarnini, S., Bartholomeusz, A., Ghany, M. G., Pawlotsky, J.-M., Liaw, Y.-F., Mizokami, M., & Kuiken, C. (2007) · Hepatology · doi:10.1002/hep.21698 · Cited by 447
Benhamou, Y., Bochet, M., Thibault, V., Di Martino, V., Caumes, E., Bricaire, F., Opolon, P., Katlama, C., & Poynard, T. (1999) · Hepatology · doi:10.1002/hep.510300525 · Cited by 424
Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region
Stuyver, L. (2001) · Hepatology · doi:10.1053/jhep.2001.22166 · Cited by 382
Long-term therapy of chronic hepatitis B with lamivudine
Lau, D. T.-Y., Khokhar, F. M., Doo, E., Ghany, M. G., Herion, D., Park, Y., Kleiner, D. E., Schmid, P., Condreay, L. D., Gauthier, J., et al. (2000) · Hepatology · doi:10.1053/jhep.2000.17912 · Cited by 348
Das, K., Xiong, X., Yang, H., Westland, C. E., Gibbs, C. S., Sarafianos, S. G., & Arnold, E. (2001) · Journal of Virology · doi:10.1128/jvi.75.10.4771-4779.2001 · Cited by 274
Identification of BMS-200475 as a potent and selective inhibitor of hepatitis B virus
Innaimo, S. F., Seifer, M., Bisacchi, G. S., Standring, D. N., Zahler, R., & Colonno, R. J. (1997) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.41.7.1444 · Cited by 273
A heteroaryldihydropyrimidine activates and can misdirect hepatitis B virus capsid assembly
Stray, S. J., Bourne, C. R., Punna, S., Lewis, W. G., Finn, M. G., & Zlotnick, A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0409732102 · Cited by 267
Naturally Occurring Variants of Hepatitis B Virus
Günther, S., Fischer, L., Pult, I., Sterneck, M., & Will, H. (1999) · Advances in Virus Research · doi:10.1016/s0065-3527(08)60298-5 · Cited by 255
Metadata
- Authors
- Ling, R., Mutimer, D., Ahmed, M., Boxall, E. H., Elias, E., Dusheiko, G. M., & Harrison, T. J.
- Venue
- Hepatology
- Published
- 1996-09
- Volume
- 24
- Issue
- 3
- Pages
- 711-713
- ISSN
- 0270-9139 (ISSN-L)
- OpenAlex
- W2042653073
- Cited by
- 466
- References
- 9
- FWCI
- 48.01
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.